Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B.
Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, Guner R, Dogan Z, Kucukazman M, Poyrazoglu OK, Biyik M, Ozturk NA, Aydogan T, Coban S, Kocaman O, Sapmaz F, Gokturk SH, Karaca C, Demirezer A, Tanoglu A, Yildirim B, Altinbas A, Atak BM, Cosar AM, Alkan E; Other collaborators.
Koklu S, et al. Among authors: altinbas a.
Aliment Pharmacol Ther. 2015 Feb;41(3):310-9. doi: 10.1111/apt.13036. Epub 2014 Dec 4.
Aliment Pharmacol Ther. 2015.
PMID: 25982037